Study finds MLH1 associated with worse outcomes in EC
MutL homolog 1 promoter hypermethylation (MLH1ph) is a molecular marker that identifies a distinct, higher-risk subgroup in EC.
News
-
-
Lower dose of pembrolizumab may be effective in EC
Low doses of pembrolizumab could be effective in Asian patients with EC, who tend to have a lower BMI than Western populations.
-
Case report examines robot-assisted surgery for endometrial cancer
Robot-assisted surgery can potentially lead to better outcomes among patients with endometrial cancer.
-
Integration of AI may improve endometrial cancer care
The integration of AI into various aspects of endometrial cancer care may mean better screening and disease monitoring.
-
Study finds mixed emotions after fertility-sparing treatment
Fertility-sparing treatment for endometrial cancer showed high response and pregnancy rates, but ongoing worries were common.
-
Older patients with endometrial cancer less likely to choose chemotherapy
Though older individuals with EC are less likely overall to desire chemotherapy, there is wide variation in opinions, a study found.
-
Obesity linked to poorer response to pembrolizumab in endometrial cancer
A study found that progression-free survival, but not overall survival, was worse among obese patients with EC treated with pembrolizumab.
-
Ultrasound scoring system helps predict risk of endometrial cancer
A study showed the high-risk of endometrial cancer (HIREC) score can improve the prediction of high-risk cancers preoperatively.
-
Vaginal brachytherapy beneficial in recurrent endometrial cancer
Vaginal brachytherapy is beneficial in some women with endometrial cancer who developed vaginal recurrence.
-
Exercise improves quality of life after endometrial cancer treatment
A scoping review maps exercise programs studied after endometrial cancer treatment and highlights early benefits and research gaps.
